Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Dose-Ranging Study to Assess the Safety and Anti-Cytomegalovirus Activity of Maribavir versus Valganciclovir for the Treatment of CMV Infections in Transplant Recipients Who Do Not Have CMV Organ Disease

Trial Profile

A Phase 2, Randomized, Dose-Ranging Study to Assess the Safety and Anti-Cytomegalovirus Activity of Maribavir versus Valganciclovir for the Treatment of CMV Infections in Transplant Recipients Who Do Not Have CMV Organ Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maribavir (Primary) ; Valganciclovir
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Shire ViroPharma; ViroPharma Incorporated
  • Most Recent Events

    • 29 Jul 2020 Results assessing the viral mutations and associated drug resistance phenotypes detected at baseline and after maribavir therapy in patients enrolled in trials 202 and 203 published in the Journal of Infectious Diseases
    • 24 Sep 2019 According to a Takeda Pharma media release, Johan Maertens (M.D., Ph.D. of Universitaire Ziekenhuizen Leuven in Leuven, Belgium) is the trials principal investigator and lead author.
    • 24 Sep 2019 Results presented in a Takeda Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top